Delisting risk
Radiopharm Theranostics (ADR) (RADX)
Develops targeted radiopharmaceutical diagnostics and therapies for solid tumors.
$2.02
Pre-market−0.11 (−5.16%)
At close$2.13(−6.17%)
Something off on this page? Send us feedback.
EPSReportedEstimate
——————Feb '26Aug '26
Reported——————−$2.25−$1.67
Estimate——————−$1.51−$1.67
Surprise——————−49.0%0.0%
RevenueReportedEstimate
——————Feb '26Aug '26
Reported——————$987.4K$845.2K
Estimate——————$664.5K$845.2K
Surprise——————+48.6%0.0%
History
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Aug 2026 | −$1.67 | −$1.67 | 0.0% |
| Feb 2026 | −$1.51 | −$2.25 | −49.0% |
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Aug 28, 2026 | −$1.67 | −$1.67 | 0.0% | $845.2K | $845.2K | 0.0% | −5.4% |
| Feb 27, 2026 | −$1.51 | −$2.25 | −49.0% | $664.5K | $987.4K | +48.6% | −0.8% |